How long to take serpatinib and when it can be safely stopped

Selpatinib, as a targeted therapy drug targeting RET gene fusions or mutations, plays an important role in the treatment of malignant tumors such as non-small cell lung cancer and thyroid cancer. However, questions about how long it should be taken and when it can be safely discontinued are not set in stone and need to be determined on a patient-specific basis.

The course of treatment with serpatinib is based on the patient's tumor characteristics, disease severity, and overall health, among other factors. Therefore, the duration of administration may vary between patients. Generally speaking, patients with malignant tumors such as non-small cell lung cancer and thyroid cancer may need to take serpatinib continuously for several months or even longer.

During the treatment process, doctors will closely monitor the patient's condition and drug response, and adjust the treatment plan according to the actual situation. If the curative effect is good, the patient can continue to maintain the current dose of treatment; if adverse reactions or worsening of the condition occur, the doctor may adjust the dose or change the treatment plan.

After continuing to take serpatinib for a period of time, if the patient's condition is stably controlled or the predetermined treatment goals are achieved, doctors may consider gradually reducing the dose or discontinuing the drug. This procedure needs to be done under close supervision by a doctor to ensure patient safety.

Although serpatinib is effective in many patients, some may experience intolerable side effects. In this case, the doctor may consider reducing the dose, temporarily discontinuing the medication, or switching to another treatment.

If serpatinib does not significantly improve a patient's condition, or if the patient's condition progresses, the doctor may recommend stopping the drug and exploring other treatment options.

References:

https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/selpercatinib